Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2017

View Archived Issues

AntriaBio selects lead oral plasma kallikrein inhibitor candidates

InMed reports preclinical results in development of INM-405 for pain

OncBioMune Pharmaceuticals preparing clinical testing of OvcaVax

Lilly and CureVac enter global immune-oncology collaboration to develop mRNA cancer vaccines

Synspira commences phase Ia study of lead candidate for cystic fibrosis

Novartis starts phase I study of NMDA receptor NAM triggering milestone payment to Cadent

NexImmune, The Leukemia & Lymphoma Society to develop immunotherapy for AML

AST-2818 demonstrates antitumoral activity against EGFR T790M mutant NSCLC

Johnson & Johnson reviews highlights of third quarter 2017

Herpes vaccine HSV-529 safe and immunogenic in phase I trial

FDA gives fast track status to Radius Health's elacestrant

AbbVie and Harpoon Therapeutics enter immuno-oncology research collaboration

Mitsubishi Tanabe Pharma's acquisition of NeuroDerm complete

EMA grants orphan drug designation to Conatus' IDN-7314 for primary sclerosing cholangitis

Otsuka submits NDA for nalmefene in Japan

FDA advisory committee recommends approval of once-weekly semaglutide for type 2 diabetes

First-in-human phase I results presented for JNJ-64041757 immunotherapy in lung cancer

Astellas announces a new collaborative research agreement with TB Alliance

FDA approves CAR T therapy Yescarta for adults with relapsed or refractory large B-cell lymphoma

Sage Therapeutics describes novel NMDA receptor modulators

New glucosylceramidase activators identified at Lysosomal Therapeutics

FDA grants priority review to sNDA for Lynparza

AstraZeneca synthesizes novel serine-protein kinase ATM inhibitors

FluGen receives a grant from DOD to test universal flu vaccine against mismatched strains

University of Texas, Immune Sensor divulge new cyclic GMP-AMP synthase inhibitors

Loxo Oncology reports results from committee assessment of larotrectinib dataset

Protalix Biotherapeutics licenses PRX-102 to Chiesi outside U.S.

Vir Biotechnology collaborates with Alnylam and Visterra to develop programs for infectious diseases

Phase II luminespib study in non-small cell lung cancer meets primary endpoint

CEBPA gene novel mutation found to cause congenital lipodystrophy